IBRX SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending
12 juil. 2023 14h08 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, July 12, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Class Period: May 23, 2022...
IBRX INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations Regarding FDA Complete Response Letter
18 mai 2023 13h11 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, May 18, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Visit:...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations Regarding FDA Complete Response Letter
11 mai 2023 16h58 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Visit:...